Plain-English translation of NCT06334120 on ClinicalTrials.gov ↗ · Source last updated ·
This is a safety monitoring study of darolutamide, a medication already approved and prescribed by doctors to treat certain types of prostate cancer. Researchers will collect information from the medical records of men in Korea who are already taking this medication as part of their regular cancer care. The study aims to learn more about how safe and effective the treatment is in real-world use.
Even though this medication is already approved and available, doctors and patients benefit from understanding how it works and any side effects it might cause when used in everyday practice, especially in different populations like Korean patients.
You likely qualify if…
You likely don't qualify if…
You will continue taking your medication and seeing your doctor as you normally would — about every 2 to 4 months for routine cancer check-ups, scans, and blood tests. Researchers will simply review your medical records and ask you about any side effects or other medications you're taking. Your participation lasts about one year, and the entire study will run for about six years.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
South Korea